[1] CDC. Opioid prescribing is still high and varies widely throughout the U.S[EB/OL]. (2017-07-06)[2017-08-22]. https://www.cdc.gov/media/releases/2017/p0706-opioid.html. [2] Havens Jennifer R,Lofwall Michelle R,Frost Simon D W, et al. Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users[J]. Am J Public Health, 2013, 103(1): e44-52. [3] Matthew Miller MD MPH ScD, Til Stürmer MD MPH, Azrael D, et al. Opioid Analgesics and the Risk of Fractures in Older Adults with Arthritis[J]. Journal of the American Geriatrics Society, 2011, 59(3):430. [4] Creanga A A, Sabel J C, Ko J Y, et al. Maternal drug use and its effect on neonates: a population-based study in Washington State[J]. Obstetrics & Gynecology, 2012, 119(5):924. [5] FDA. Timeline of Selected FDA Activities and Significant Events Addressing Opioid Misuse andAbuse[EB/OL].(2017-08-20)[2017-08-23].https://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm338566.htm. [6] Rudd R A, Seth P, David F, et al. Increases in Drug and Opioid-Involved Overdose Deaths-United States, 2010-2015[J]. Mmwr Morbidity & Mortality Weekly Report, 2016, 65(5051):1445. [7] CDC.Wide-ranging online data for epidemiologic research (WONDER). Atlanta, GA: US Department of Health and Human Services, CDC, National Center for Health Statistics; 2017[EB/OL]. (2017-06-27)[2017-08-23]. https://wonder.cdc.gov. [8] Florence C S, Zhou C, Luo F, et al. The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013[J]. Medical Care, 2016, 54(10):901. [9] Centers for Disease Control and Prevention(CDC). Vital signs: overdoses of prescription opioid pain relievers-United States, 1999-2008[J]. MMWR Morb. Mortal. Wkly. Rep., 2011, 60(43): 1487-1492. [10] University of Wisconsin Pain & Policy Studies Group. Global Opioid Consumption, 2015[EB/OL].(2015)[2017-08-23]http://www.painpolicy.wisc.edu/global. [11] 邹武捷,满春霞,杨淑苹,等. 麻醉药品和精神药品管制研究Ⅱ-美国管制物质的管制历程与现状[J]. 中国药房, 2017, 28(1):10-14. [12] DEA. Title 21 United States Code (USC) Controlled Substances Act[EB/OL].(2017-07-17)[2017-08-23].https://www.deadiversion.usdoj.gov/21cfr/21usc/index.html. [13] DEA. DEA proposes reduction to amount of controlled substances to be manufactured in 2018[EB/OL].(2017-08-04)[2017-08-22].https://www.dea.gov/divisions/hq/2017/hq080417.shtml. [14] DEA. Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpro-panolamine for 2013[J].Federal Register,2013,78(152):48193-48197. [15] DEA. Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpro-panolamine for 2014[J]. Federal Register,2014,79(164):50700-50704. [16] DEA. Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpro-panolamine for 2015[J]. Federal Register,2015;80(179):55642-55646. [17] DEA. Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpro-panolamine for 2016[J]. Federal Register,2016,81(206):73421-73426. [18] DEA. Proposed Adjustments to the Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2017[J]. Federal Register,2017,82(149):36449-36453. [19] DEA. Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropan-olamine for 2018[J]. Federal Register,2017,82(150):36830-36834. [20] CDC. OpioidPrescribing[EB/OL]. (2017-07-06)[2017-08-22]. https://www.cdc.gov/vitalsigns/opioids/index.html. [21] CDC. New data show continuing opioid epidemic in the United States.[EB/OL](2016-12-16)[2017-08-23].https://www.cdc.gov/media/releases/2016/p1216-continuing-opioid-epidemic.html. [22] CDC. CDC awards $12 million to help states fight opioid overdose epidemic[EB/OL]. (2017-07-17)[2017-08-23]. https://www.cdc.gov/media/releases/2017/p0717-opioid-funding.html. [23] BBC. Trump urged to declare national emergency over opioid crisis[EB/OL]. (2017-08-01) [2017-08-23]. http://www.bbc.com/news/world-us-canada-40793540. [24] FDA. FDA Perspective on AbuseDeterrent Opioid Development. [EB/OL]. (2017-03-07) [2017-08-23].https://www.fda.gov/downloads/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm545923.pdf. [25] 李淑芳, 潘文灏. 美国FDA基于品种的药品风险管理计划研究与制定[J]. 中国药物警戒, 2013, 10(3):144-147. [26] FDA. Abuse-Deterrent Opioids-Evaluation and Labeling Guidance for Industry[EB/OL]. [2017-08-24].https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf. [27] FDA.General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products Guidance for Industry[EB/OL].[2017-08-24]. https://www.fda.gov/downloads/Drugs/Guidance Compliance Regulatory Information/Guidances/UCM492172. pdf. [28] FDA强化阿片类药物标签的警告信息[J].上海医药, 2013,(19):62-62. [29] FDA. New Safety Measures Announced for Immediate Release (IR) Opioids[EB/OL].(2016-03-22)[2017-08-24].https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm491437.htm. [30] FDA. Califf, FDA top officials call for sweeping review of agency opioids policies[EB/OL]. (2016-02-04)[2017-08-24].https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm484765.htm. [31] FDA. FDA requests removal of Opana ER for risks related to abuse[EB/OL].(2017-06-8)[2017-08-24].https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm562401.htm. [32] Califf Robert M,Woodcock Janet,Ostroff Stephen. A Proactive Response to Prescription Opioid Abuse[J].N. Engl. J. Med., 2016, 374(15): 1480-1485. [33] DEA.DEA's Community Outreach Section[EB/OL]. [2017-08-24].https://www.dea.gov/prevention/overview.shtml. [34] DEA.DEA Releases New Rules That Create Convenient But Safe and Secure Prescription Drug Disposal Options[EB/OL]. (2014-09-08)[2017-09-01]. https://www.dea.gov/divisions/hq/2014/hq090814.shtml. [35] DEA. DEA Brings in Record Amount of Unused Prescription Drugs on National Prescription Take Back Day[EB/OL]. (2017-03-08)[2017-08-25]. https://www.dea.gov/divisions/hq/2017/hq050817a.shtml. [36] DEA. Working Together to Break the Cycle of Drug Tracking, Drug Violence, and Drug Abuse[EB/OL]. (2017-02) [2017-08-25]. https://www.dea.gov/prevention/360-strategy/360_Fact_Sheet.pdf. [37] DEA. To Combat Today's Opioid Crisis, DEA and Discovery Education Launch Powerful New Middle and High School Education Program Operation Prevention[EB/OL]. (2016-10-25)[2017-08-25]. https://www.dea.gov/divisions/hq/2016/hq102516.shtml. [38] DEA. DRUG PREVENTION PUBLICATIONS[EB/OL]. [2017-08-24]. https://www.dea.gov/pr/publications.shtml. [39] CDC. Our History-Our Story[EB/OL]. (2016-04-26)[2017-08-25]. https://www.cdc.gov/about/history/index.html. [40] CDC. About the Morbidity and Mortality Weekly Report (MMWR) Series[EB/OL]. (2017-06-16)[2017-08-25]. https://www.cdc.gov/mmwr/about.html. [41] CDC. Guideline Resources[EB/OL]. (2017-08-31)[2017-09-01]. https://www.cdc.gov/drugoverdose/prescribing/resources.html. [42] Dowell D, Haegerich T M, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain-United States,V2016[J]. Jama, 2016, 315(15):1624-1645. [43] CDC. What States Need to Know about PDMPs[EB/OL]. (2017-08-28)[2017-09-01].https://www.cdc.gov/drugoverdose/pdmp/states.html. |